Psychometric validation of the BDI-II among HIV-positive CHARTER study participants.

TitlePsychometric validation of the BDI-II among HIV-positive CHARTER study participants.
Publication TypeJournal Article
Year of Publication2015
AuthorsHobkirk, AL, Starosta, AJ, De Leo, JA, Marra, CM, Heaton, RK, Earleywine, M
Corporate AuthorsCHARTER Group
JournalPsychol Assess
Volume27
Issue2
Pagination457-66
Date Published2015 Jun
ISSN1939-134X
Abstract

Rates of depression are high among individuals living with HIV. Accurate assessment of depressive symptoms among this population is important for ensuring proper diagnosis and treatment. The Beck Depression Inventory-II (BDI-II) is a widely used measure for assessing depression, however its psychometric properties have not yet been investigated for use with HIV-positive populations in the United States. The current study was the first to assess the psychometric properties of the BDI-II among a large cohort of HIV-positive participants sampled at multiple sites across the United States as part of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. The BDI-II test scores showed good internal consistency (α = .93) and adequate test-retest reliability (internal consistency coefficient = 0.83) over a 6-mo period. Using a "gold standard" of major depressive disorder determined by the Composite International Diagnostic Interview, sensitivity and specificity were maximized at a total cut-off score of 17 and a receiver operating characteristic analysis confirmed that the BDI-II is an adequate diagnostic measure for the sample (area under the curve = 0.83). The sensitivity and specificity of each score are provided graphically. Confirmatory factor analyses confirmed the best fit for a three-factor model over one-factor and two-factor models and models with a higher-order factor included. The results suggest that the BDI-II is an adequate measure for assessing depressive symptoms among U.S. HIV-positive patients. Cut-off scores should be adjusted to enhance sensitivity or specificity as needed and the measure can be differentiated into cognitive, affective, and somatic depressive symptoms.

DOI10.1037/pas0000040
Alternate JournalPsychol Assess
PubMed ID25419643
PubMed Central IDPMC4442079
Grant ListF32 DA038519 / DA / NIDA NIH HHS / United States
HHS-N-270-2010-00030C / / PHS HHS / United States
HHS-N-271-2010-00036C / / PHS HHS / United States
HHSN271201000036C / MH / NIMH NIH HHS / United States
P30 MH062512 / MH / NIMH NIH HHS / United States